Ketamine clinical trials, in English

Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies.

NCT02543983 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments.

NCT03065335 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

Background: Most drugs that treat mood disorders take a long time to work. Certain receptors in the brain might help ketamine work.

NCT03973268 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

Background: More than 12,000 people have taken part in research at the Experimental Therapeutics \& Pathophysiology Branch at the National Institute of Mental Health Intramural Program. This has led to advances in the treatment of depression, bipolar disorder, and suicide risk.

NCT04877977 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (major depression).

NCT05327699 · Official ClinicalTrials.gov record · Emory University

The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls. Patients will be recruited from an inpatient psychiatric unit.

NCT05450432 · Official ClinicalTrials.gov record · Massachusetts General Hospital

The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. this study wants to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

NCT05915013 · Official ClinicalTrials.gov record · Yale University

The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function.

NCT06090422 · Official ClinicalTrials.gov record · University Hospital of North Norway

The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are: * to see if Esketamine is effective when added to ongoing antidepressant treatment * to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice Participants will: * attend the clinic for supervised self-administration of intranasal Esketamine treatment * be observed for 2 hours following Esketamine administration including blood pressure monitoring * be asked to complete a battery of questionnaires * be reimbursed for travel expenses

NCT06103760 · Official ClinicalTrials.gov record · Royal North Shore Hospital

The goal of this study is to compare the effectiveness of two formulations of ketamine - Spravato® and racemic ketamine - in people with treatment-resistant depression (TRD). The main questions it aims to answer are: * How the two formulations compare in terms of their effectiveness in treating TRD.

NCT06278779 · Official ClinicalTrials.gov record · The George Institute

Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments.

NCT06462196 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion.

NCT06480201 · Official ClinicalTrials.gov record · Texas A&M University

Background: Major depressive disorder (major depression) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat major depression, but it can take a long time for them to be effective.

NCT06511908 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

The proposed study is a single-site, randomly assigned, controlled clinical trial (RCT) comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of ketamine administered in a medical model without psychotherapy (KET). Eligible study you would be adults with major depressive disorder (major depression).

NCT06559826 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

This is a pilot clinical trial to assess the feasibility, safety, and preliminary how well it works of ketamine-assisted group therapy for Spanish-speaking adults with depression

NCT06597695 · Official ClinicalTrials.gov record · Juliana Zambrano, MD, MPH

This study wants to to measure the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.

NCT06668571 · Official ClinicalTrials.gov record · Mayo Clinic

This study wants to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for use in the treatment of treatment-resistant depression (TRD) and Esketamine (Spravato®), taken as a nasal spray which has received FDA approval for use in the treatment of treatment-resistant depression (TRD) in the treatment of patients with treatment-resistant depression (TRD). The study will look at the following: * How well the treatment helps with symptoms of depression (effectiveness), * How comfortable and willing people are to use the treatment (acceptability), and * How well people can deal with any side effects from the treatment (tolerability).

NCT06713616 · Official ClinicalTrials.gov record · Yale University

This watch-and-measure (no experimental treatment required) protocol is intended to provide long-term follow-up data on patients initiating or continuing treatment with either Spravato® or IV ketamine. This can provide us information on the patient acceptability and satisfaction, patterns of use, long-term effectiveness, and safety of the two approaches.

NCT06725277 · Official ClinicalTrials.gov record · Yale University

This study wants to identify pharmacokinetics of postpartum ketamine infusion. This study will assess ketamine kinetics and metabolism in this setting.

NCT06767566 · Official ClinicalTrials.gov record · University of Utah

Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to begin to work and do not work at all for many people.

NCT06781697 · Official ClinicalTrials.gov record · Sunnybrook Health Sciences Centre

In the treatment of Major Depressive Disorder (major depression), ketamine can produce rapid but short-lasting improvements in mood. In order to develop a new generation of treatments with rapid and sustained how well it works, a better understanding of the mechanism of action is urgently needed.

NCT06788249 · Official ClinicalTrials.gov record · University of Pennsylvania

To explore the how well it works of a single low dose of esketamine for patients with irritable bowel syndrome (IBS).

NCT06788444 · Official ClinicalTrials.gov record · Beijing Tiantan Hospital

Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration.

NCT06835504 · Official ClinicalTrials.gov record · Columbia University

The goal of this clinical trial is to treat active suicidal ideation in individuals with Major Depressive Disorder (major depression) using ketamine and to understand suicidal ideation by examining biological mechanisms using magnetic resonance imaging (MRI), and psychological mechanisms through validated clinical scales and qualitative interviews. The main questions it aims to answer are: 1.

NCT06891300 · Official ClinicalTrials.gov record · The Royal's Institute of Mental Health Research

This is a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment phase 3 clinical trial evaluating the additive effect of intravenous ketamine in combination with electroconvulsive therapy (ECT) in patients with treatment-resistant major depressive disorder (major depression). The study aims to determine whether ketamine enhances the antidepressant how well it works of ECT and reduces associated cognitive side effects.

NCT07088380 · Official ClinicalTrials.gov record · Università Vita-Salute San Raffaele

This study wants to evaluate how well JNJ-54135419 works (how well it works) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (major depression, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activities) as compared with psychoactive dummy treatment (placebo) (does not contain JNJ-54135419) plus SoC in adolescent participants with acute suicidal ideation or behavior.

NCT07227454 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (major depression) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a dummy treatment (placebo) (a look-alike capsule with no medicine) to reduce symptoms of depression?

NCT07284667 · Official ClinicalTrials.gov record · ACADIA Pharmaceuticals Inc.

This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participants who are receiving ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment at the MGH Ketamine Clinic.

NCT07563868 · Official ClinicalTrials.gov record · Massachusetts General Hospital

The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality Disorder and either Major Depressive Disorder or Bipolar Disorder. The main question it aims to answer is: Does IV ketamine and DBT produce more rapid and robust improvements in suicidal ideation (SI) severity between baseline and Day 35 compared to IV midazolam and DBT, as measured by changes in the Modified Scale for Suicidal Ideation (MSSI) scores ?

NCT07569198 · Official ClinicalTrials.gov record · Joshua Rosenblat

Depressive symptoms are common among patients admitted to the intensive care unit (ICU) and may adversely affect recovery, participation in care, treatment adherence, quality of life, and outcomes after critical illness. Conventional antidepressants have limited utility for rapidly treating depressive symptoms during an ICU admission because of their delayed onset of action and potential drug interactions in medically complex patients.

NCT07639359 · Official ClinicalTrials.gov record · Hospital Italiano de Buenos Aires

Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments.

NCT07680140 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University

Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments.

NCT07706478 · Official ClinicalTrials.gov record · Senz

This study wants to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with dummy treatment (placebo) in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder \[major depression\] who have not responded to at least 2 different antidepressant treatments given at an adequate dose for an adequate duration in the current episode of depression).

NCT07716098 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

The goal of this clinical trial is to see if combining ketamine with behavioral activation (BA) therapy to treat moderate to severe treatment-resistant depression improves depressive symptoms and general functioning more than ketamine alone. We aim to find out whether participants who receive both treatments: 1.

NCT07801703 · Official ClinicalTrials.gov record · The Royal's Institute of Mental Health Research